After the USPSTF advised against prostate cancer screening for all men, there was a decrease in the incidence of the disease.
Chemotherapy-induced periphreal neuropathy can affect patients' daily living, and some individuals may be more prone to it than others.
It is estimated that 8%-18% of all cancer patients will have preexisting diabetes at the time they are diagnosed with cancer.
"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes most medical professionals."
Lenvatinib is approved in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer who have disease progression after systemic therapy, are not candidates for curative surgery or radiation, and who are mismatch repair proficient or not microsatellite instability–high.
Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
The reality of the COVID-19 pandemic will force lawmakers to firmly act on behalf of antibiotic policies, according to an expert with Pew Charitable Trusts.
Diversity, equity, and inclusion must be a centerpiece of nursing recruitment and retention.
Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.
Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.
Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.
Experts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.
Updates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.
This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.
Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.
Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
When engaging with a family member of a patient who has died, nurses should consider using immediate interventions aimed at supporting the loved ones who are in shock and in pain following their loss.
Jennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.
Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.
Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.
"Over the last decade, the landscape of systemic anti-cancer therapy has changed dramatically following the approvals of multiple new targeted therapies," - Kerin Adelson, MD.
Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
According to Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN, patients with newly diagnosed myeloproliferative neoplasms may be unaware of the questions they should be asking their providers.
Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.
Seventy-three percent of advanced practice providers reported that they are interested in becoming more involved with clinical trials.